I. Bodrogi

16.4k total citations · 4 hit papers
78 papers, 10.3k citations indexed

About

I. Bodrogi is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, I. Bodrogi has authored 78 papers receiving a total of 10.3k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Surgery, 28 papers in Pulmonary and Respiratory Medicine and 27 papers in Oncology. Recurrent topics in I. Bodrogi's work include Testicular diseases and treatments (32 papers), Renal cell carcinoma treatment (10 papers) and Cancer Treatment and Pharmacology (8 papers). I. Bodrogi is often cited by papers focused on Testicular diseases and treatments (32 papers), Renal cell carcinoma treatment (10 papers) and Cancer Treatment and Pharmacology (8 papers). I. Bodrogi collaborates with scholars based in Hungary, France and United States. I. Bodrogi's co-authors include Oliver Sartor, Stéphane Oudard, Liji Shen, Ivo Kocák, Johann S. de Bono, Gwénaëlle Gravis, Mustafa Özgüroğlu, Steinbjørn Hansen, Jean-Pascal Machiels and Mary J. MacKenzie and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

I. Bodrogi

71 papers receiving 10.1k citations

Hit Papers

Temsirolimus, Interferon Alfa, or Both for Advanced Renal... 2000 2026 2008 2017 2007 2010 2007 2000 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
    2007 2.8k citations I. Bodrogi et al. profile →
  2. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
    2010 2.4k citations I. Bodrogi et al. The Lancet profile →
  3. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
    2007 1.7k citations Bernard Escudier, A Płużańska et al. The Lancet profile →
  4. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
    2000 1.7k citations Hans von der Maase, Steen Werner Hansen et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
I. Bodrogi Hungary 20 6.4k 4.3k 3.6k 2.9k 2.4k 78 10.3k
Christine Théodore France 39 6.0k 0.9× 2.1k 0.5× 3.5k 1.0× 1.7k 0.6× 3.9k 1.6× 164 10.5k
Christian Kollmannsberger Canada 63 8.7k 1.4× 5.5k 1.3× 4.8k 1.4× 3.4k 1.2× 4.2k 1.7× 387 14.0k
Frédéric Rolland France 33 6.7k 1.0× 4.8k 1.1× 4.3k 1.2× 3.0k 1.0× 2.7k 1.1× 142 11.6k
Ugo De Giorgi Italy 51 4.7k 0.7× 2.3k 0.5× 3.8k 1.1× 2.4k 0.8× 2.1k 0.9× 489 9.0k
Charles M. Baum United States 35 8.2k 1.3× 5.9k 1.4× 4.7k 1.3× 3.4k 1.1× 1.4k 0.6× 71 12.8k
Gary R. Hudes United States 40 6.8k 1.1× 6.1k 1.4× 3.5k 1.0× 3.6k 1.2× 1.2k 0.5× 102 10.7k
Gwénaëlle Gravis France 41 6.3k 1.0× 2.2k 0.5× 3.4k 1.0× 2.1k 0.7× 1.4k 0.6× 368 9.2k
Sergio Bracarda Italy 38 7.6k 1.2× 5.8k 1.3× 4.4k 1.2× 3.8k 1.3× 2.1k 0.8× 236 11.6k
Jorge A. García United States 43 6.2k 1.0× 2.6k 0.6× 2.1k 0.6× 2.4k 0.8× 1.1k 0.4× 213 8.1k
Ronald B. Natale United States 44 7.6k 1.2× 3.9k 0.9× 8.4k 2.4× 1.5k 0.5× 3.1k 1.3× 170 13.8k

Countries citing papers authored by I. Bodrogi

Since Specialization
Citations

This map shows the geographic impact of I. Bodrogi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Bodrogi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Bodrogi more than expected).

Fields of papers citing papers by I. Bodrogi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Bodrogi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Bodrogi. The network helps show where I. Bodrogi may publish in the future.

Co-authorship network of co-authors of I. Bodrogi

This figure shows the co-authorship network connecting the top 25 collaborators of I. Bodrogi. A scholar is included among the top collaborators of I. Bodrogi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Bodrogi. I. Bodrogi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Maase, Hans von der, Steen Werner Hansen, J.T. Roberts, et al.. (2023). Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study. Journal of Clinical Oncology. 41(23). 3881–3890. 19 indexed citations
2.
Géczi, Lajos, et al.. (2020). Neutrophil-to-lymphocyte ratio in primary mediastinal germ cell tumors: A retrospective analysis of >20 years single institution experience. Current Problems in Cancer. 44(4). 100537–100537. 2 indexed citations
3.
4.
Horti, J, Anders Widmark, Arnulf Stenzl, et al.. (2009). A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel/Prednisolone in Patients with Hormone-Refractory Prostate Cancer. Cancer Biotherapy and Radiopharmaceuticals. 24(2). 175–180. 39 indexed citations
5.
Théodore, Christine, Iwona Skoneczna, I. Bodrogi, et al.. (2008). A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Annals of Oncology. 19(7). 1304–1307. 78 indexed citations
6.
Escudier, Bernard, A Płużańska, P. Koralewski, et al.. (2007). Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. The Lancet. 370(9605). 2103–2111. 1722 indexed citations breakdown →
7.
Géczi, Lajos, Zoltán Doleschall, I. Bodrogi, et al.. (2004). Expression and prognostic value of the lung resistance-related protein (LRP) in germ cell testicular tumors.. PubMed. 24(2C). 1097–104. 6 indexed citations
8.
Leo, Angelo Di, Stephen Chan, Marianne Paesmans, et al.. (2004). HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel. Breast Cancer Research and Treatment. 86(3). 197–206. 121 indexed citations
9.
Géczi, Lajos, I. Bodrogi, József Tóth, et al.. (2004). Clinical relevance of HER-2/neu expression in germ-cell testicular tumors.. PubMed. 24(4). 2219–24. 15 indexed citations
10.
Gundy, S., et al.. (2004). Increased predisposition to cancer in brothers and offspring of testicular tumor patients. Pathology & Oncology Research. 10(4). 197–203. 23 indexed citations
11.
Géczi, Lajos, et al.. (2003). Expression of HER-2/neu in testicular tumors.. PubMed. 23(4). 3447–51. 14 indexed citations
12.
Géczi, Lajos, et al.. (2002). [Lung resistance protein analysis in testicular cancer].. PubMed. 46(4). 339–45. 1 indexed citations
13.
Maase, Hans von der, Steen Werner Hansen, J.T. Roberts, et al.. (2000). Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study. Journal of Clinical Oncology. 18(17). 3068–3077. 1678 indexed citations breakdown →
14.
Gershanovich, M., Daniel de Castro, H. Lurie, et al.. (1999). [Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer].. PubMed. 45(4). 361–8. 1 indexed citations
15.
16.
Gershanovich, M., H.A. Chaudri, H. Lurie, et al.. (1998). Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Annals of Oncology. 9(6). 639–645. 206 indexed citations
17.
18.
Gundy, S., et al.. (1992). Persistence of Chromosomal Aberrations in Blood Lymphocytes of Testicular Cancer Patients. Oncology. 49(5). 376–380. 17 indexed citations
19.
Gundy, S., et al.. (1990). Persistence of Chromosomal Aberrations in Blood Lymphocytes of Testicular Cancer Patients. Oncology. 47(5). 410–414. 9 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christine Théodore Breakdown of academic impact, for papers by Christian Kollmannsberger Breakdown of academic impact, for papers by Frédéric Rolland Breakdown of academic impact, for papers by Ugo De Giorgi Breakdown of academic impact, for papers by Charles M. Baum Breakdown of academic impact, for papers by Gary R. Hudes Breakdown of academic impact, for papers by Gwénaëlle Gravis Breakdown of academic impact, for papers by Sergio Bracarda Breakdown of academic impact, for papers by Jorge A. García Breakdown of academic impact, for papers by Ronald B. Natale
Rankless by CCL
2026